Pacific Edge Ltd
NZX:PEB
Pacific Edge Ltd
Revenue
Pacific Edge Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pacific Edge Ltd
NZX:PEB
|
Revenue
NZ$21.8m
|
CAGR 3-Years
31%
|
CAGR 5-Years
40%
|
CAGR 10-Years
34%
|
|
|
Aroa Biosurgery Ltd
ASX:ARX
|
Revenue
NZ$69.1m
|
CAGR 3-Years
46%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
Pacific Edge Ltd
Glance View
Pacific Edge Ltd. engages in the discovery and commercialization of diagnostic and prognostic technology for the early detection and monitoring of cancer. The firm develops and commercializes diagnostic and prognostic tools for the early detection and management of cancers. The firm's segments include NZ Laboratory, US Laboratory and Research NZ & Australia. Its segments are engaged in the research and development of diagnostic and prognostic products for human cancer both in New Zealand and Australia, and operation of the laboratories used for the detection of bladder cancer in the United States and New Zealand. The company offers Cxbladder, which is a suite of non-invasive laboratory tests for the detection and the management of bladder cancer. Cxbladder includes a suite of urine-based molecular tests to determine the likelihood of bladder cancer in patients presenting with hematuria. Its pipeline includes Cxcolorectal, which is a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancer, enabling prediction of aggressiveness of the tumor.
See Also
What is Pacific Edge Ltd's Revenue?
Revenue
21.8m
NZD
Based on the financial report for Sep 30, 2024, Pacific Edge Ltd's Revenue amounts to 21.8m NZD.
What is Pacific Edge Ltd's Revenue growth rate?
Revenue CAGR 10Y
34%
Over the last year, the Revenue growth was -9%. The average annual Revenue growth rates for Pacific Edge Ltd have been 31% over the past three years , 40% over the past five years , and 34% over the past ten years .
You don't have any saved screeners yet